ReviewNature reviews. Urology2016
Active surveillance for prostate cancer: a narrative review of clinical guidelines.
Review in Nature reviews. Urology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 92 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
92 citing papers in PubMed, 4 syntheses or guidelines pooled it, 176 citations in OpenAlex.
- Natural history of untreated prostate cancer: a comprehensive review of long-term progression patterns and survival outcomes.Prostate cancer and prostatic diseases · 2026Pooled it
- Defining and Measuring Adherence in Observational Studies Assessing Outcomes of Real-world Active Surveillance for Prostate Cancer: A Systematic Review.European urology oncology · 2021Pooled it
- Radical prostatectomy versus deferred treatment for localised prostate cancer.The Cochrane database of systematic reviews · 2020Pooled it
- Factors Influencing Men's Choice of and Adherence to Active Surveillance for Low-risk Prostate Cancer: A Mixed-method Systematic Review.European urology · 2018Pooled it
- Artificial intelligence-enabled MRI surveillance of prostate cancer: integrating PRECISE v2, PI-QUAL, and longitudinal biomarkers-a narrative review.Abdominal radiology (New York) · 2026Review
- Impact of PSMA-Based Radiopharmaceuticals on the Clinical Management of Prostate Cancer.Cancers · 2026Article
- Does protocol heterogeneity in active surveillance influence clinical outcomes? Insights from a multicenter prostate cancer cohort.Investigative and clinical urology · 2026Article
- Multimodal artificial intelligence in urologic precision oncology: from algorithm to translational medicine (a systemized narrative review).Frontiers in oncology · 2026Review
- Article
- Long-term outcomes of active surveillance for Grade Group 1 prostate cancer and the impact of the use of MRI on overtreatment.BJU international · 2025Article
- Impact of circActa histochemica et cytochemica · 2025Article
- Review
- The 5-year results of the Stratified Cancer Active Surveillance programme for men with prostate cancer.BJU international · 2025Article
- MRI after focal therapy for prostate cancer: what radiologists must know?Abdominal radiology (New York) · 2025Review
- Exploring therapeutic applications ofFrontiers in oncology · 2025Review
- Nurses and Climate Change: A Narrative Review of Nursing Associations' Recommendations for Integrating Climate Change Mitigation Strategies.The Canadian journal of nursing research = Revue canadienne de recherche en sciences infirmieres · 2024Review
- Article
- [Cancer imaging : the official publication of the International Cancer Imaging Society · 2024Article
- Critical survival periods in prostate cancer in Sweden explored by conditional survival analysis.Cancer medicine · 2024Article
- Case report: Two cases of prostate adenocarcinoma progressing to rare sarcomatoid carcinoma with normal PSA levels following endocrine therapy.Frontiers in oncology · 2024Article
32 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 6 institutions in 5 countries.
Funding
Abstract
In the past decade active surveillance (AS) of men with localized prostate cancer has become an increasingly popular management option, and a range of clinical guidelines have been published on this topic. Existing guidelines regarding AS for prostate cancer vary widely, but predominantly state that the most suitable patients for AS are those with pretreatment clinical stage T1c or T2 tumours, serum PSA levels <10 ng/ml, biopsy Gleason scores of 6 or less, a maximum of one or two tumour-positive biopsy core samples and/or a maximum of 50% of cancer per core sample. Following initiation of an AS programme, most guidelines recommend serial serum PSA measurements, digital rectal examinations and surveillance biopsies to check for and identify pathological indications of tumour progression. Definitions of disease reclassification and progression differ among guidelines and multiple criteria for initiation of definitive treatment are proposed. The variety of descriptions of criteria for clinically insignificant prostate cancer indicates a lack of consensus on optimal AS and intervention thresholds. A single set of guidelines are needed in order to reduce variations in clinical practice and to optimize clinical decision-making. To enable truly evidence-based guidelines, further research that combines existing evidence, while also gathering information from more long-term studies is needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.